Company / Operating Cash Flow
Apellis Pharmaceuticals, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$45.3M
FY2025
5-year range
-$594.7M / $45.3M
FY2021-FY2025
Trend
+151.6%
vs FY2024
Sector context
#65 of 216
Health Care
What the data says
At $45M, Apellis Pharmaceuticals, Inc.'s operating cash flow ranks #65 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$595M in FY2023 to $45M in FY2025.
Based on SEC 10-K filings.
$45M in FY2025.
Improved from -$595M to $45M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#65 of 216 in Health CareTop 30% of 216This company $45.3M Sector average $658.7M
▼
-93.1% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 151.6% year-over-year.
- Ranks #65 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.3M | +151.6% |
| FY2024 | -$87.9M | +85.2% |
| FY2023 | -$594.7M | -15.8% |
| FY2022 | -$513.7M | +8.8% |
| FY2021 | -$563.1M | -250.9% |
| FY2020 | -$160.5M | +24.0% |
| FY2019 | -$211.1M | -60.9% |
| FY2018 | -$131.2M | -181.7% |
| FY2017 | -$46.6M | -79.2% |
| FY2016 | -$26.0M | -37.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026